Actively Recruiting

Early Phase 1
Age: 18Years - 65Years
All Genders
NCT03748446

Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

Led by Massachusetts General Hospital · Updated on 2025-05-18

20

Participants Needed

1

Research Sites

364 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The investigators will test the hypothesis that inhaled xenon will produce a rapid improvement in depressive symptoms in patients suffering from treatment-resistant depression. Specifically, the investigators will conduct a parallel randomized, double-blind crossover study that will compare the effects of xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group) to the effects of nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group). A total of 20 severely depressed patients, 10 with major depressive disorder (MDD) and 10 with Bipolar Depression (BP), will be exposed in random order to N-TAU and X-TAU in a double-blind protocol.

CONDITIONS

Official Title

Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient who meets DSM-V Criteria for MDD or Bipolar Depression as primary treatment focus
  • Able to understand risks and benefits and give informed consent
  • Age 18 to 65 years
  • Montgomery Asberg Depression Rating Scale score of 20 or higher
  • On stable antidepressant (MDD) or mood stabilizing (BP) regimen for at least 4 weeks
  • Has reliable adult transportation to and from home
  • Treating psychiatrist agrees with participation and safety plan
  • No medical contraindications to xenon or nitrogen-oxygen mixtures
  • No serious or active pulmonary disease
Not Eligible

You will not qualify if you...

  • MDD or BP with psychosis, schizophrenia, OCD, or primary anxiety disorder
  • Currently taking benzodiazepines (including PRN)
  • Unwilling or unable to follow study procedures
  • Active substance abuse in past 60 days or dependence in past 12 months
  • Current smokers of any substance including prescription marijuana
  • Pregnant or women of childbearing potential not using accepted contraception
  • Any unstable medical illness affecting cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological systems or uncontrolled seizures
  • History of brain injury or active trapped air/gas conditions (e.g., bowel obstruction, pneumothorax, pneumocephalus)
  • History of hypersensitivity to xenon or multiple adverse drug reactions
  • Use of investigational psychotropic drugs in last 6 months
  • Inability to comply with visit schedule or study procedures
  • Considered inappropriate for research participation by investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Dauten Family Center for Bipolar Treatment Innovation

Boston, Massachusetts, United States, 02114

Actively Recruiting

Loading map...

Research Team

S

Selen Amado, BA

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

NON_RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here